Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Harvard Bioscience, Inc. (HBIO) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Harvard Bioscience, Inc. (HBIO) on October 30, 2026 is 8.85 $, +0.57 % on the day. Over 52 weeks the stock traded between 3.80 $ and 9.40 $; the price now sits 90 % of the way up that range. Over the past year the price changed by +94.05 %. Market capitalization is 39.20 million $, rank 18 among 23 stocks of the same industry with a known capitalization.
Harvard Bioscience, Inc. trades on Nasdaq under the ticker HBIO. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks HBIO has traded between 3.80 $ and 9.40 $. As of 30 October 2026 the price stood 77.68 % of the way from the 52-week low to the high.
Over one year HBIO shares rose 94.05 %; over six months they rose 41.99 %. Volatility over 90 days is 41.27 %. Dividends are not included: this is price change only, as of 30 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 0.4, below the sector median of 3.6. Price to book is 5.3, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Harvard Bioscience, Inc. reported revenue of 88M $ and a net loss of 10M $ over the last four quarters. Net margin is −11.86 %. Revenue changed by −1.06 % year over year. Market capitalisation is 39M $.
HBIO has a return on equity of −140.36 %, below the sector median of −40.58 %. Return on assets is −13.65 %, above the sector median of −30.08 %. Operating margin is −0.28 %, above the sector median of −20.96 %.